RETRACTED: Levels of vascular endothelial growth factor and matrix metalloproteinase-9 proteins in patients with glioma
Authors:
Open Access
- 7 January 2014
- journal article
- retracted article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 42 (1) , 198-204
Abstract
To investigate the levels of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) proteins in patients with glioma, in order to determine if either protein has prognostic value. The presence of VEGF and MMP-9 proteins in paraffin-embedded tumour specimens from patients with glioma was detected using immunohistochemistry. The correlation between the levels of VEGF and MMP-9 proteins and tumour grade was analysed. A total of 32 patients with low-grade gliomas (World Health Organization [WHO] grade II) and 48 patients with high-grade gliomas (WHO grades III–IV) participated in the study. Positive immunohistochemical staining of VEGF and MMP-9 proteins was detected in 58/80 (72.5%) and 60/80 (75.0%) of patients, respectively. The level of VEGF immunostaining was significantly positively correlated with the level of MMP-9 immunostaining (r = 0.78). Significantly more high-grade gliomas (grades III–IV) demonstrated positive VEGF and MMP-9 immunostaining compared with the low grade gliomas (grades I–II). These data suggest that VEGF and MMP-9 play an important role in the malignant behaviour of gliomas.Keywords
This publication has 25 references indexed in Scilit:
- The role of ubiquitin-proteasome system in glioma survival and growthGrowth Factors, 2013
- The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro studyBMC Veterinary Research, 2013
- Understanding high grade glioma: Molecular mechanism, therapy and comprehensive managementCancer Letters, 2013
- Immunotherapy targeting glioma stem cells – insights and perspectivesExpert Opinion on Biological Therapy, 2011
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progressionJournal of Neuro-Oncology, 2007
- Hypoxia‐inducible factor 1α/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosisNeuropathology and Applied Neurobiology, 2004
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNature Medicine, 2004
- Gelatinase B (MMP-9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphomaInternational Journal of Cancer, 1999
- Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells.Proceedings of the National Academy of Sciences, 1994